Werbung
Werbung

VYNE

VYNE logo

VYNE Therapeutics Inc. Common Stock

0.57
USD
Gesponsert
0.00
-0.19%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

0.58

+0.01
+1.58%

VYNE Ergebnisberichte

Positives Überraschungsverhältnis

VYNE übertreffen die 20 der letzten 32Schätzungen.

63%

Nächster Bericht

Datum des nächsten Berichts
04. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$204.00K
/
-$0.18
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+20.71%
/
+5.88%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+142.86%
/
-35.71%

VYNE Therapeutics Inc. Common Stock earnings per share and revenue

On 06. Nov. 2025, VYNE reported earnings of -0.17 USD per share (EPS) for Q3 25, missing the estimate of -0.13 USD, resulting in a -28.21% surprise. Revenue reached 169.00 tausend, compared to an expected 102.00 tausend, with a 65.69% difference. The market reacted with a +4.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.18 USD, with revenue projected to reach 204.00 tausend USD, implying an increase of 5.88% EPS, and increase of 20.71% in Revenue from the last quarter.
FAQ
For Q3 2025, VYNE Therapeutics Inc. Common Stock reported EPS of -$0.17, missing estimates by -28.21%, and revenue of $169.00K, 65.69% above expectations.
The stock price moved up 4.59%, changed from $0.34 before the earnings release to $0.35 the day after.
The next earning report is scheduled for 04. März 2026.
Based on 5 analysts, VYNE Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of $204.00K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung